<DOC>
	<DOCNO>NCT00893113</DOCNO>
	<brief_summary>The purpose study assess effect Alfuzosin treat Erectile Dysfunction men mild low urinary tract symptom base upon change baseline erectile function ( EF ) domain International Index Erectile Function ( IIEF ) .</brief_summary>
	<brief_title>An Efficacy Study Evaluate Alfuzosin Treat Men With Erectile Dysfunction Mild Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This protocol placebo-controlled , double-blind , crossover trial . Patients screen randomize Group A Group B 1:1 ratio receive placebo tablet daily Alfuzosin ( 10 mg ) daily 12 week . Patients crossover original placebo group receive Alfuzosin 12 week original Alfuzosin group receive placebo . At every visit patient complete IIEF AUA symptom index .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Male , 3069 year age Has mild moderate Erectile Dysfunction score &lt; 25 EF domain IIEF AUA score less equal 14 Negative urinalysis evidence Urinary Tract Infection Blood pressure &lt; 90/50 &gt; 170/110 Neurological disorder ( MS , SCI , CVA , Parkinson 's disease , ALS ) Diabetes Mellitus History PSA &gt; 10 History confirm suspected prostate cancer History Moderate/Severe Hepatic Insufficiency define &gt; 2X ULN On Alpha Blocker PDE 5 inhibitor within 2 week randomization Receive treatment investigational agent within 30 day prior enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>